Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs placebo on oxidative stress biomarkers in diabetic patients with systolic heart failure
IRCT20120215009014N484Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and type 2 diabetes mellitus (T2DM) comparing Empagliflozin adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Change in serum oxidative stress biomarkers. Started Oct 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20120215009014N484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N484.